The protein is implicated in a wide swath of cancers, but harnessing it for drug R&D is still a major scientific challenge.
Phase II Study of Samotolisib in Children and Young Adults With Tumors Harboring Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Pathway Alterations: Pediatric MATCH APEC1621D In a RET-fusion ...
Kymera Therapeutics Inc. has published the characterization of KT-253, a novel compound designed to degrade the murine double minute 2 (MDM2) protein, offering a promising approach for cancers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results